

IST-3 Bibliography: published full papers in peer-reviewed journals

1. Innes K. Thrombolysis for acute ischaemic stroke: core nursing requirements. *British Journal of Nursing* 2003;12(7):416-24
2. Kane I, Lindley R, Lewis S, Sandercock P. Impact of stroke syndrome and stroke severity on the process of consent in the Third International Stroke Trial. *Cerebrovascular Diseases* 2006;21:348-52
<http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=91541&Ausgabe=231712&ProduktNr=224153&filename=91541.pdf>
3. Whiteley W, Lindley R, Wardlaw J, Sandercock P. Third International Stroke Trial. *Int J Stroke*. 2006;1:172-6.
<http://onlinelibrary.wiley.com/doi/10.1111/j.1747-4949.2006.00043.x/full>
4. Sandercock P, Lindley R, Wardlaw J, Protocol 06PRT/1269: Third International Stroke Trial (IST-3). *Lancet*
<http://www.thelancet.com/journals/lancet/misc/protocol/06PRT-1269>.
5. Wardlaw JM, Bath P, Sandercock P, Perry D, Palmer J, Watson G, Lloyd S, Geddes J, Farrall A. The NeuroGrid stroke exemplar clinical trial protocol. *Int J Stroke*. 2007;2:63-9 <http://onlinelibrary.wiley.com/doi/10.1111/j.1747-4949.2007.00092.x/full>
6. The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Sandercock P, Lindley R, Wardlaw J, Dennis M, Lewis S, Venables G, Kobayashi A, Czlonkowska A, Berge E, Bruins Slot K, Murray V, Peeters A, Hankey G, Matz K, Brainin M, Ricci S, Celani MG, Righetti E, Cantisani T, Gubitz G, Phillips S, Arauz A, Prasad K, Correia M, Lyrrer P; the IST-3 collaborative group. *Trials* 2008;9(1):37. <http://www.trialsjournal.com/content/9/1/37>
7. SCOPE (Stroke Complications and Outcomes Prediction Engine) Collaborations and IST. Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3). *JNNP* 2008;79:397-400
<http://jnnp.bmj.com/content/79/4/397.full.pdf+html>
8. EPITHET-where next? Sandercock P, Wardlaw J, Dennis M, Lindley R, Hankey G, Matz K, Peeters A, Phillips S, Gubitz G, Prasad K, Ricci S, Celani MG, Righetti E, Cantisani T, Arauz A, Berge E, Slot KB, Kobayashi A, Czlonkowska A, Correia M, Murray V, Lyrrer P, Venables G; IST-3 Collaborative Group. *Lancet Neurology* 2008;7(7):570-1.
[http://www.thelancet.com/journals/laneur/article/PIIS1474-4422\(08\)70123-6/fulltext](http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(08)70123-6/fulltext)
9. Mangset M, Forde R, Nessa J, Berge E, Wyller TB. "I don't like that, it's tricking people too much": acute informed consent to participation in a trial of thrombolysis for stroke. *J Med Ethics* 2008 Sep 30;34(10):751.
<http://jme.bmj.com/cgi/content/full/34/10/751>
10. Mangset M, Berge E, Forde R, Nessa J, Wyller TB. "Two per cent isn't a lot, but when it comes to death it seems quite a lot anyway": patients' perception of risk and willingness to accept risks associated with thrombolytic drug treatment for acute stroke. *J Med Ethics* 2008 Dec 22;35(1):42. <http://jme.bmj.com/cgi/content/full/35/1/42>
11. Oxfordshire community stroke project clinical stroke syndrome and appearances of tissue and vascular lesions on pre-treatment CT in hyper-acute ischemic stroke among the first 510 patients in the Third International Stroke Trial (IST-3). Kobayashi A, Wardlaw J, Lindley R, Lewis S, Sandercock P, Czlonkowska A; IST-3 Collaborative Group. *Stroke* 2009;40(3):743-8.
<http://stroke.ahajournals.org/content/40/3/743.full>
12. Should more patients with acute ischaemic stroke receive thrombolytic treatment? Wardlaw J, Murray V, Sandercock P, BMJ 2009; 339. <http://www.bmj.com/content/339/bmj.b4584>
13. The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients? Czlonkowska A, Kobayashi A, Lewis S, Sandercock P, Lindley R, Baranska-Gieruszczak M on behalf of the IST-3 collaborative group. *Polish Journal of Neurology and Neurosurgery*. 2009; 43, 3:228-235.
<http://www.termedia.pl/Original-paper-The-Third-International-Stroke-Trial-Thrombolysis-IST-3-in-Poland-are-we-recruiting-the-right-patients-15.12742.0.1.html>
14. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Sandercock P, Lindley R, Wardlaw J, Dennis M, Lewis S, Venables G, Kobayashi A, Czlonkowska A, Berge E, Bruins Slot K, Murray V, Peeters A, Hankey G, Matz K, Brainin M, Ricci S, Celani MG, Righetti E, Cantisani T, Gubitz G, Phillips S, Arauz A, Prasad K, Correia M, Lyrrer P; the IST-3 collaborative group. *Trials* 2011, 12:252
<http://www.trialsjournal.com/content/12/1/252>
15. How many patients might receive thrombolytic therapy in the light of the ECASS-3 and IST-3 data? Jan Bembenek, Adam Kobayashi, Peter Sandercock, Anna Czlonkowska. *Int J Stroke* 2010; 5:428–431.
<http://onlinelibrary.wiley.com/doi/10.1111/j.1747-4949.2010.00479.x/full>
16. 'Where are we now with intravenous thrombolysis for acute ischaemic stroke'? Peter Sandercock, Joanna Wardlaw, and Richard Lindley. *Int J Stroke* 2010; 5: 381–382: <http://onlinelibrary.wiley.com/doi/10.1111/j.1747-4949.2010.00465.x/abstract>
17. Statistical analysis plan for the third International Stroke Trial (IST-3); part of a 'thread' of reports of the trial. *Int J Stroke* 2012; 7: 186–18. <http://onlinelibrary.wiley.com/doi/10.1111/j.1747-4949.2012.00782.x/full>
18. The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. *Lancet* 2012; 379(9834):2352-2363.
[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(12\)60768-5/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/fulltext)
19. Wardlaw J M, Murray V, Berge E, del Z G, Sandercock P, Lindley R L et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. *Lancet* 2012; 379(9834):2364-2372.
[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(12\)60738-7/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60738-7/fulltext)
20. IST-3 Collaborative Group. Effect of thrombolysis with alteplase within 6h of acute ischaemic stroke on long-term outcomes (the third international stroke trial [IST-3]): 18-month follow-up of a randomised controlled trial. *Lancet Neurology* 2013;12:768-76. doi:10.1016/S1474-4422(13)70130-3.
[http://www.thelancet.com/journals/laneur/article/PIIS1474-4422\(13\)70130-3/fulltext](http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(13)70130-3/fulltext)

21. Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, Sandercock P. Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome. An analysis of the Third International Stroke trial. *Stroke* 2014;45:1000-6: <http://dx.doi.org/10.1161/STROKEAHA.113.004362>
22. Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J et al. Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on All-Cause Mortality (Third International Stroke Trial). *Stroke* Published online before print November 4, 2014, <http://dx.doi.org/10.1161/STROKEAHA.114.006890>
23. Arauz A, Berge E, Sandercock P. Third International Stroke Trial 3: an update. *Curr Opin Neurol* 2014 February;27(1):8-12
24. Wardlaw JM, Carpenter T, Sakka E, Mair G, Cohen G, Shuler K, et al. Imaging perfusion deficits arterial patency and thrombolysis safety and efficacy in acute ischaemic stroke. An observational study of the effect of advanced imaging methods in The Third International Stroke Trial (IST-3), a randomised controlled trial. *Efficacy Mech Eval* 2014;1(1) <http://www.journalslibrary.nihr.ac.uk/eme/volume-1/issue-1#hometab0>
25. Mair G, von Kummer R, Adami A, White PM, Adams ME, Yan B et al. Observer reliability of CT angiography in the assessment of acute ischaemic stroke: data from the Third International Stroke Trial. *Neuroradiology* 2015; 57(1):1-9. <http://dx.doi.org/10.1007/s00234-014-1441-0>
26. Impact of treatment delay, age and stroke severity of the effects of intravenous thrombolysis with alteplase in acute ischaemic stroke: an individual participant data meta-analysis of randomised trials Emberson J and the Stroke Thrombolysis Trialists Collaboration *Lancet*. 2014 Aug 5. pii: S0140-6736(14)60584-5. [http://dx.doi.org/10.1016/S0140-6736\(14\)60584-5](http://dx.doi.org/10.1016/S0140-6736(14)60584-5) .
27. Mair G, Boyd EV, Chappell FM, von Kummer R, Lindley RI, Sandercock P, Wardlaw JM IST-3 Collaborative Group. Sensitivity and specificity of the Hyperdense Artery Sign for arterial obstruction in acute ischemic stroke *Stroke* 2015;46(1):102-7. <http://dx.doi.org/10.1161/STROKEAHA.114.007036>
28. Lindley RI, Wardlaw JM, Whiteley WN, Cohen G, Blackwell L, Murray GD et al. Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial. *Stroke* 2015 March;46(3):746-56. <http://dx.doi.org/10.1161/STROKEAHA.114.006573>
29. The IST-3 collaborative Group. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial. *The Lancet Neurology* 2015 May;14(5):485-96. [http://dx.doi.org/10.1016/S1474-4422\(15\)00012-5](http://dx.doi.org/10.1016/S1474-4422(15)00012-5)
30. MHRA expert review of alteplase for stroke 2015. <https://www.gov.uk/government/publications/alteplase-for-treatment-of-acute-ischaemic-stroke-independent-review>
31. Pooja Khatri, Darren Tayama, Geoff Cohen, Richard I. Lindley, Joanna M. Wardlaw, Sharon D. Yeatts, Joseph P. Broderick, and Peter Sandercock on behalf of the PRISMS and IST-3 Collaborative Groups. Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis. *Stroke*. 2015;46:2325-2327. <http://dx.doi.org/10.1161/STROKEAHA.115.009951>
32. Wardlaw JM, von Kummer R, Carpenter T, Parsons M, Lindley RI, Cohen G, Murray V, Kobayashi A, Peeters A, Chappell F, Sandercock PAG. Protocol for the perfusion and angiography imaging sub-study of the Third International Stroke Trial (IST-3) of alteplase treatment within six-hours of acute ischemic stroke. *Int J Stroke* 2015 August 1;10(6):956-68. <http://dx.doi.org/10.1111/j.1747-4949.2012.00946.x>
33. Berge E, Cohen G, Lindley RI, Sandercock P, Wardlaw JM, Sandset EC, Whiteley W. Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke. *Stroke* 2015 December;46(12):3362-9
34. Mair G, von Kummer R+, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PAG, Lindley RI, Wardlaw JM, For the IST-. Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke. *Neurology* 2015 December 9. <http://dx.doi.org/10.1212/WNL.0000000000002236.1526-632>
35. Mair G, von Kummer R, Lindley RI, Sandercock PAG, Wardlaw JM, IST-3 Collaborative Group (2015) Effect of X-Ray Attenuation of Arterial Obstructions on Intravenous Thrombolysis and Outcome after Ischemic Stroke. *PLoS ONE* 2015 10(12): e0145683 <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145683>
36. Access to IST-3 data. Sandercock P, Wardlaw J, Lindley R, Whiteley W, Cohen G. *Lancet* 2016. 387: 1904. [doi:10.1016/S0140-6736\(16\)30414-7](https://doi.org/10.1016/S0140-6736(16)30414-7)
37. What are the risks of intracranial haemorrhage due to alteplase after acute ischaemic stroke? Results from an individual patient data meta-analysis of randomised trials. Whiteley W, Emberson J. Lees K et al On behalf of the Stroke Thrombolysis Trialists' Collaborators Group. *The Lancet Neurology* 2016 August;15(9):925-33. Published **Online** June 8, 2016 [http://dx.doi.org/10.1016/S1474-4422\(16\)30076-X](http://dx.doi.org/10.1016/S1474-4422(16)30076-X)
38. Eivind Berge, Melinda Roaldsen, William Whiteley, Geoff Cohen, Erik Lundström, Ann-Sofie Rudberg, John Forbes, Joel Smith, Karsten Bruins Slot, Peter Sandercock on behalf of the IST-3 collaborative group. Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on Long-term Mortality: the Third International Stroke Trial [IST-3]. *Lancet Neurology* 2016 Published **Online** July 19, 2016 [http://dx.doi.org/10.1016/S1474-4422\(16\)30139-9](http://dx.doi.org/10.1016/S1474-4422(16)30139-9)
39. Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA et al. Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials. *Stroke* 2016 September;47(9):2373-9.
40. Sposato LA, Cohen G, Wardlaw JM, Sandercock P, Lindley RI, Hachinski V. Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial). *Stroke* 2016 December;47(12):2959-65.
41. Samuel O Danso, Dominic Job, David Rodriguez, David Alexander Dickie, Jeb Palmer, Jenny Ure, Philip M Bath, Peter AG Sandercock and Joanna M Wardlaw*. Developing an integrated image bank and metadata for large scale research in

- cerebrovascular disease: our experience from the Stroke Image Bank Project. *Frontiers in Neuroscience* Front. ICT 2016 3:32 <https://doi.org/10.3389/fict.2016.00032>
42. Arterial obstruction on CT or MR angiography and response to intravenous thrombolytics in ischemic stroke. Grant Mair, Rüdiger von Kummer, Alessandro Adami, Philip M White, Matthew E Adams, Bernard Yan, Andrew M Demchuk, Andrew J Farrall, Robin J Sellar, Eleni Sakka, Jeb Palmer, David Perry, Richard I Lindley, Peter AG Sandercock, Joanna M Wardlaw for the IST-3 Collaborative Group, *Stroke* 2017; 48: 353-360. <http://dx.doi.org/10.1161/STROKEAHA.116.015164>
 43. Arba F, Mair G, Carpenter T, Sakka E, Sandercock PAG, Lindley RI, et al. Cerebral White Matter Hypoperfusion Increases with Small-Vessel Disease Burden. Data From the Third International Stroke Trial. *J Stroke Cerebrovasc Dis* 2017 Jul;26(7):1506-13. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2017.03.002>
 44. Dickie DA, Aribisala B, Mair G, Berge E, Lindley RI, Sandercock P, et al. Blood pressure variability and leukoaraiosis in acute ischemic stroke. *Int J Stroke* 2017 Sep 5;1747493017729267
 45. Hacke W, Lyden P, Emberson J, Baigent C, Blackwell L, Sandercock P, et al. Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. *Int J Stroke* 2017 Nov 24; <http://journals.sagepub.com/doi/full/10.1177/1747493017744464>.
 46. Karen J Ferguson, Vera Cvoro, Alasdair MJ MacLulich, Susan D Shenkin, Peter AG Sandercock, Eleni Sakka, Joanna M Wardlaw Visual rating scales of white matter hyperintensities and atrophy: comparison of computed tomography and magnetic resonance imaging. *Journal of Stroke and Cerebrovascular Diseases* 2018. <https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.02.028>
 47. Rudberg A-SR, Berge E, Gustavsson A, Nasman P, Lundstrom E. Long-term health-related quality of life, survival and costs by different levels of functional outcome six months after stroke. *European Stroke Journal* 2018 Jan 9;2396987317753444. <https://doi.org/10.1177/396987317753444>.
 48. Chen L, Carlton Jones AL, Mair G, Patel R, Gontsarova A, Ganesalingam J, et al. Rapid Automated Quantification of Cerebral Leukoaraiosis on CT Images: A Multicenter Validation Study. *Radiology* 2018 Aug;288(2):573-81. <https://doi.org/10.1148/radiol.2018171567>
 49. Effect of IV alteplase on the ischemic brain lesion at 24–48 hours after ischemic stroke. Grant Mair, Rüdiger von Kummer, Zoe Morris, Anders von Heijne, Nick Bradey, Lesley Cala, André Peeters, Andrew J Farrall, Alessandro Adami, Gillian Potter, Peter AG Sandercock, Richard I Lindley, Joanna M Wardlaw for the IST-3 Collaborative Group. *Neurology*. 2018;00:1-11. <http://dx.doi.org/10.1212/WNL.0000000000006575>
 50. Observer Agreement on Computed Tomography Perfusion Imaging in Acute Ischemic Stroke. Salwa El-Tawil, MD*; Grant Mair, MD*; Xuya Huang, MD; Eleni Sakka, MSc; Jeb Palmer, MSc; Ian Ford, PhD; Lalit Kalra, PhD; Joanna Wardlaw, MD†; Keith W. Muir, MD† *Stroke*. 2019;50:3108-3114. <http://dx.doi.org/10.1161/STROKEAHA.119.026238>
 51. Improving Clinical Detection of Acute Lacunar Stroke Analysis From the IST-3. Arba, Francesco; Mair, Grant; Phillips, Stephen, Sandercock P, Wardlaw J, IST-3 group. *Stroke* 2020; 51 (5); 1411-1418 <https://doi.org/10.1161/STROKEAHA.119.028402>

Editorials and commentaries on IST-3 since 2012

1. Lyden PD. In anticipation of International Stroke Trial-3 (IST-3). *Stroke* 2012;43:1691-4
2. Leys L, Cordonnier C. rt-PA for ischaemic stroke: what will the next question be?. *Lancet* 2012;379:2320-1
3. Donnan GA, Davis SM. IST-3: a major contribution to thrombolysis research. *International Journal of Stroke* 2012;7:566-7
4. Furlan AJ. IST-3: no pragmatic answers. *International Journal of Stroke* 2012;7:568-9
5. Hoffman JR, Cooper RJ. How is more negative evidence being used to support claims of benefit: the curious case of the international stroke trial (IST-3). *Emergency Medicine Australasia* 2012;24:473-6
6. Fatovich DM. Believing is seeing: stroke thrombolysis remains unproven after the third international stroke trial (IST-3). *Emergency Medicine Australasia* 2012;24:477-9
7. Kleinig TJ, Churilov L, Parsch CS, Dewey HM, Barber PA. Stroke thrombolysis and the third international stroke trial: examining "the totality of the evidence". *Emergency Medicine Australasia* 2012;25:107-9
8. Hughes S. IST-3: tPA benefits sustained out to 18 months. *Medscape*. 2013. Article ID 806690. [<http://www.medscape.com>]
9. Anderson C. Thrombolysis with alteplase after stroke: extending outcomes. *Lancet Neurology* 2013;12:731-2
10. Anon. Evidence and doubt in the translation of research into care. *Lancet* 2014;384:638'
11. Larrue V. Brain CT signs and the effect of alteplase after stroke. *Lancet Neurol* 2015 May;14(5):458-60.
12. Seitz RJ. The pros and cons of intravenous thrombolysis in stroke. *The Lancet Neurology* 2016 September;15(10):997-8.

Correspondence since 2012

1. Fatovich DM, MacDonald SP, Brown SG, Smith B, Newman DH, Shreves AE, Barer D, Durtis D, Sandercock P, Wardlaw J, Dennis M, Murray G, Lindley R. Thrombolysis in acute ischaemic stroke. *Lancet* 2012;380:1053-5
2. Shinton R, Sandercock P, Wardlaw JM, Hudson I. Questions about authorisation of alteplase for ischaemic stroke. *Lancet* 2014;384:659-63
3. Dai Q, Sun W, Liu X, Whiteley WN, Thompson D, Sandercock P. Letter by Dai et al regarding article "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial". *Stroke* 2014;45:e132-3

4. Berge E, Cohen G, Wardlaw JM, Sandercock PA, Whiteley WN. Mortality after thrombolysis - Authors' reply. *Lancet Neurol* 2016 December;15(13):1305.

Abstracts published since trial results made public in 2012

1. Sandercock P, Wardlaw JM, Lindley RI, Dennis MS, Cohen G. The third international stroke trial (IST-3) main results part I: primary and secondary outcomes among 3035 patients randomised. *Cerebrovascular Diseases* 2012;33 Suppl 2:16
2. Lindley RI, Sandercock P, Wardlaw JW, Dennis MS, Cohen G. The third international stroke trial (IST-3) of thrombolysis main results III. Effect of iv thrombolysis with iv t-PA on death or dependency in the 3035 patients randomized: subgroup analysis. *Cerebrovascular Diseases* 2012;33(suppl 2):79 (Abst.1) [Ref 19448]
3. Roots A, Birns J, Bhalla A, Rudd A. Nurse-led telemedicine-directed hyper-acute stroke trial randomisation and management of post-thrombolysis anaphylaxis. *Cerebrovascular Diseases* 2012;33(suppl 2):477-8 (Abst.2022) [Ref 19403]
4. Farrall A, Wardlaw J, Sandercock P, Lindley R, Cohen G, von Kummer R, et al. The third international stroke trial (IST-3) of intravenous thrombolysis with rt-PA: baseline imaging features among 3035 patients randomised. *International Journal of Stroke* 2012;7 Suppl 2:61-2 (Abst.142)
5. Sandercock P; IST-3 Collaborative Group. The Third International Stroke Trial (IST-3) of thrombolysis. Main results & implications for clinical practice. *Cerebrovascular Diseases* 2012;34 Suppl 1:6-7 (Abst.S5-1)
6. Sandercock PAG, Wardlaw JM, Lindley RI, Cohen G; IST3 collaborative group. The third international stroke trial (IST-3) of intravenous rt-PA: effect of age and time on treatment effect among 3035 patients randomised. *International Journal of Stroke* 2012;7 Suppl 2:6
7. Lindley RI, Sandercock PA, Wardlaw JM, Dennis MS, Cohen G, IST-3 Collaborative Group. Third international stroke trial (IST-3): subgroup effects of iv rt-PA < 6 hrs in acute ischemic stroke on symptomatic intracranial haemorrhage and outcome at 6 months. *Stroke* 2013;44 (Abst.TMP23)
8. Sandercock PA, Wardlaw JM, Lindley RI, Dennis MS, IST-3 Collaborative Group. Third international stroke trial (IST-3): effect of iv rt-pa < 6 hours in acute ischaemic stroke on living circumstances and health related quality of life at six months. *Stroke* 2013;44 (Abst.WMP22)]
9. Wardlaw J, Carpenter T, von Kummer R, Cohen G, Lindley R, Sandercock P. Perfusion imaging in patients randomised to rt-PA or control in the third international stroke trial (IST-3): baseline characteristics and association with outcome. *Stroke* 2013;44 (Abst.A10)
10. Wardlaw J, von Kummer R, Farrall A, Cala L, von Heijne A, Peeters A, et al. The impact of ischemic and structural brain tissue changes on response to rt-PA: an analysis of imaging from 3035 patients in the third international stroke trial. *Stroke* 2013;44 (Abst.A104)
11. Sandercock P, Wardlaw J, Dennis M, Cohen G, Whiteley W, Lindley, et al. Impact of thrombolysis on important aspects of daily life at 18 months in the third International Stroke Trial (IST-3). *International Journal of Stroke* 2013;8 Suppl 3:4
12. Whiteley WN, Cohen G, Wardlaw J, Lindley R, Sandercock PAG. IST-3 trial: impact of rt-PA on survival to 18 months post ischaemic stroke. *Cerebrovascular Diseases* 2013;35(Suppl 3):19 (Abst.6)
13. Sandercock PAG, Lindley RI, Wardlaw JM, Dennis MS, Cohen G. The third international stroke trial (IST-3): benefits of iv thrombolysis on functional outcome and health-related quality of life (HRQoL) persist to 18 months after treatment. *Cerebrovascular Diseases* 2013;35(Suppl 3):34 (Abst.4)
14. Wardlaw JM, Carpenter T, Cohen G, von Kummer R, Lindley R, Sandercock P. Does perfusion imaging lesion size or mismatch influence six month outcomes after rt-PA given up to six hours after acute ischaemic stroke? The third International Stroke Trial (IST-3). *Cerebrovascular Diseases* 2013;35(Suppl 3):111 (Abst.12)
15. Whiteley WN, Thompson D, Cohen G, Lindley R, Wardlaw JM, Sandercock PAG. Predictions of intracranial haemorrhage and the risks and benefits of rtPA in acute ischaemic stroke: an analysis of the IST-3 trial. *Cerebrovascular Diseases* 2013;35(Suppl 3):169 (Abst.4)
16. Mair G, Wardlaw JM, Sandercock P, Lindley R, von Kummer R. Combining CT angiography with non-contrast CT to predict infarct on follow up CT in acute ischaemic stroke. Substudy analysis of imaging from the third International Stroke Trial (IST-3). *Cerebrovascular Diseases* 2013;35(Suppl 3):237 (Abst.15)
17. Mair G, Wardlaw JM, Sandercock P, Lindley R, von Kummer R, Farrall AJ. Association of non-contrast CT and CT angiography with baseline clinical deficit and functional outcome. Substudy analysis of imaging from the third International Stroke Trial (IST-3). *Cerebrovascular Diseases* 2013;35(Suppl 3):405 (Abst.226)
18. Sakka E, Perry D, Buchanan D, Innes K, Sandercock P, Lindley RI, Wardlaw JM. Medical image management for multicentre trials. Experience from the Third International Stroke Trial (IST-3) with 6576 scans. *Cerebrovascular Diseases* 2013;35(Suppl 3):562 (Abst.24)
19. Mair G, Wardlaw JM, von Kummer R, Sandercock PA. Response to thrombolysis treatment in ischemic stroke patients with and without arterial occlusion on computed tomographic angiography: the Third International Stroke Trial. *Stroke* 2014;45(Suppl 1) (Abst.A6)
20. Khatri P, Tayama D, Cohen G, Lindley RI, Wardlaw JM, Yeatts SD, et al. Effect of IV rtPA in mild strokes in the third international stroke trial (IST3): a post hoc analysis. *Stroke* 2014;45(Suppl 1) (Abst.ATMP21)
21. Coutts SB, Lindley R, Hill MD, Cohen G, Wardlaw J, Sandercock P on behalf of the TEMPO and IST-3 Investigators. Effect of thrombolysis in a minor stroke population. Analysis of minor stroke patients treated in the IST-3 study. *Cerebrovascular diseases* 2014;37(suppl 1): p156

22. Eivind Berge, Melinda Roaldsen, William Whiteley, Geoff Cohen, Erik Lundström, Ann-Sofie Rudberg, John Forbes, Joel Smith, Karsten Bruins Slot, Peter Sandercock on behalf of the IST-3 collaborative group Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on Long-term Mortality: the Third International Stroke Trial [IST-3] (accepted for ESOC 2016, Barcelona).
23. Grant Mair, Trevor Carpenter, Geoff Cohen, Richard Lindley, Peter Sandercock, Joanna Wardlaw Visual scoring versus computational volume measures of perfusion defects in acute ischaemic stroke. (accepted for ESOC 2016, Barcelona)

Link to video of public lecture on stroke and thrombolysis by Peter Sandercock

<http://www.ed.ac.uk/schools-departments/clinical-brain-sciences/news/latest-news/public-lectures-epilepsy-stroke>

Reference List

- (1) Larrue V. Brain CT signs and the effect of alteplase after stroke. *Lancet Neurol* 2015 May;14(5):458-60.